Michael W Konstan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2661620/publications.pdf

Version: 2024-02-01

204 papers	22,566 citations	10351 72 h-index	9073 144 g-index
209 all docs	209 docs citations	209 times ranked	11907 citing authors

#	Article	IF	Citations
1	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	13.9	1,920
2	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	13.9	1,308
3	Cystic fibrosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1229-1256.	2.5	859
4	Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis. New England Journal of Medicine, 1995, 332, 848-854.	13.9	746
5	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation. New England Journal of Medicine, 2010, 363, 1991-2003.	13.9	741
6	Inflammatory cytokines in cystic fibrosis lungs.. American Journal of Respiratory and Critical Care Medicine, 1995, 152, 2111-2118.	2.5	677
7	Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 448-454.	2.5	504
8	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation. Thorax, 2012, 67, 12-18.	2.7	466
9	Genetic Modifiers of Lung Disease in Cystic Fibrosis. New England Journal of Medicine, 2005, 353, 1443-1453.	13.9	442
10	Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. Journal of Pediatrics, 2007, 151, 134-139.e1.	0.9	384
11	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	5.2	372
12	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. Journal of Cystic Fibrosis, 2015, 14, 419-430.	0.3	371
13	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. Journal of Pediatrics, 2003, 142, 624-630.	0.9	355
14	Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis.. American Journal of Respiratory Cell and Molecular Biology, 1995, 13, 257-261.	1.4	334
15	Association Between Respiratory Tract Methicillin-Resistant S<emph type="ital">taphylococcus aureus</emph> and Survival in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2010, 303, 2386.	3.8	312
16	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	5.2	301
17	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	2.5	300
18	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis, 2011, 10, 54-61.	0.3	284

#	Article	IF	Citations
19	A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. Journal of Pediatrics, 2001, 139, 813-820.	0.9	278
20	Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology. , 1997, 24, 137-142.		274
21	Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution. Human Gene Therapy, 2004, 15, 1255-1269.	1.4	265
22	Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.. Journal of Clinical Investigation, 1997, 100, 2810-2815.	3.9	247
23	Altered respiratory epithelial cell cytokine production in cystic fibrosisâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 72-78.	1.5	238
24	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respiratory Medicine,the, 2017, 5, 107-118.	5.2	235
25	Pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2004, 37, 400-406.	1.0	215
26	The Role of Inflammation in the Pathophysiology of CF Lung Disease. Clinical Reviews in Allergy and Immunology, 2002, 23, 005-028.	2.9	214
27	Factors Influencing Outcomes in Cystic Fibrosis. Chest, 2003, 123, 20-27.	0.4	208
28	Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection. Thorax, 2013, 68, 818-825.	2.7	206
29	Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 822-828.	2.5	202
30	Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 836-842.	2.5	198
31	Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. American Journal of Human Genetics, 2014, 94, 233-245.	2.6	193
32	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respiratory Medicine,the, 2014, 2, 902-910.	5.2	191
33	Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. Journal of Cystic Fibrosis, 2020, 19, 68-79.	0.3	185
34	Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatric Pulmonology, 2007, 42, 307-313.	1.0	173
35	Clinical Use of Ibuprofen Is Associated with Slower FEV₁ Decline in Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1084-1089.	2.5	166
36	Impact of Pregnancy on Women With Cystic Fibrosis. Chest, 2006, 129, 706-711.	0.4	165

#	Article	IF	Citations
37	Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. Journal of Pediatrics, 1994, 124, 689-693.	0.9	162
38	Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. , 1999, 28, 231-241.		161
39	Leukotriene B₄Markedly Elevated in the Epithelial Lining Fluid of Patients with Cystic Fibrosis. The American Review of Respiratory Disease, 1993, 148, 896-901.	2.9	155
40	Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax, 2018, 73, 731-740.	2.7	152
41	Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease. Proceedings of the American Thoracic Society, 2007, 4, 406-417.	3.5	148
42	Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatric Pulmonology, 2011, 46, 230-238.	1.0	144
43	Presence of methicillin resistantStaphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatric Pulmonology, 2007, 42, 513-518.	1.0	139
44	Ibuprofen Attenuates the Inflammatory Response toPseudomonas aeruginosain a Rat Model of Chronic Pulmonary Infection: Implications for Antiinflammatory Therapy in Cystic Fibrosis1-4. The American Review of Respiratory Disease, 1990, 141, 186-192.	2.9	136
45	Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 617-626.	5.2	129
46	Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. , 1999, 28, 231.		126
47	Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes. Journal of Cystic Fibrosis, 2013, 12, 461-467.	0.3	125
48	Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. Journal of Cystic Fibrosis, 2014, 13, 139-147.	0.3	123
49	IL-10 Attenuates Excessive Inflammation in Chronic Pseudomonas Infection in Mice. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 2040-2047.	2.5	120
50	A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Cystic Fibrosis, 2014, 13, 148-155.	0.3	119
51	Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clinical and Translational Gastroenterology, 2017, 8, e81.	1.3	107
52	Effect of Pseudomonas Infection on Weight Loss, Lung Mechanics, and Cytokines in Mice. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 271-279.	2.5	105
53	Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects. Journal of Pediatrics, 1991, 118, 956-964.	0.9	104
54	Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Statistics in Medicine, 2002, 21, 1271-1287.	0.8	102

#	Article	IF	Citations
55	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 241-248.	0.3	102
56	Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 135-143.	1.0	99
57	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	1.0	99
58	Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 250-256.	0.3	98
59	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 405-411.	0.3	96
60	Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Quality of Life Research, 2012, 21, 1267-1278.	1.5	95
61	Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis, 2010, 9, 1-16.	0.3	93
62	Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis. Journal of Pediatrics, 2009, 155, 634-639.e4.	0.9	92
63	Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials. Pediatric Pulmonology, 2004, 37, 385-392.	1.0	91
64	Classifying Severity of Cystic Fibrosis Lung Disease Using Longitudinal Pulmonary Function Data. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 780-786.	2.5	91
65	The Use of Anti-inflammatory Medications in Cystic Fibrosis. Chest, 1999, 115, 1053-1058.	0.4	90
66	Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology, 2014, 49, 650-658.	1.0	90
67	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 610-623.	1.0	88
68	Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio. Antimicrobial Agents and Chemotherapy, 2011, 55, 1684-1692.	1.4	88
69	Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. , 1999, 28, 248-254.		86
70	Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis. Clinics in Chest Medicine, 2007, 28, 331-346.	0.8	85
71	The Efficacy and Safety of Meropenem and Tobramycin vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis. Chest, 2005, 128, 2336-2346.	0.4	82
72	Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis. Pediatric Research, 1997, 41, 161-165.	1.1	81

#	Article	IF	Citations
73	Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 1086-1091.	1.3	78
74	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508delâ€CFTR. Annals of the American Thoracic Society, 2017, 14, 213-219.	1.5	78
75	Clinical use of dornase alfa is associated with a slower rate of FEV₁ decline in cystic fibrosis. Pediatric Pulmonology, 2011, 46, 545-553.	1.0	76
76	Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. Journal of Pediatrics, 2001, 139, 572-577.	0.9	73
77	Prolonged Inflammatory Response to AcutePseudomonasChallenge in Interleukin-10 Knockout Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1176-1181.	2.5	73
78	Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Advanced Drug Delivery Reviews, 2002, 54, 1409-1423.	6.6	73
79	Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis. Journal of Pediatrics, 2008, 153, 746-751.e2.	0.9	72
80	Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology, 2017, 52, 909-915.	1.0	71
81	Elastin and collagen degradation products in urine of patients with cystic fibrosis.. American Journal of Respiratory and Critical Care Medicine, 1995, 152, 157-162.	2.5	69
82	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis, 2018, 17, 484-491.	0.3	63
83	Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 78-83.	0.3	62
84	BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. Journal of Cystic Fibrosis, 2014, 13, 156-163.	0.3	61
85	Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function. Pediatrics, 2007, 119, e531-e537.	1.0	60
86	Ibuprofen therapy for cystic fibrosis lung disease: revisited. Current Opinion in Pulmonary Medicine, 2008, 14, 567-573.	1.2	58
87	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 2010, 45, 1167-1172.	1.0	58
88	Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatric Pulmonology, 2002, 33, 142-150.	1.0	57
89	Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 874-881.	1.0	56
90	Long-term Effects of Pregnancy and Motherhood on Disease Outcomes of Women with Cystic Fibrosis. Annals of the American Thoracic Society, 2013, 10, 213-219.	1.5	56

#	Article	IF	Citations
91	Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a009779-a009779.	2.9	54
92	Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respiratory Research, 2010, 11, 137.	1.4	53
93	Characterizing aggressiveness and predicting future progression of CF lung disease. Journal of Cystic Fibrosis, 2009, 8, S15-S19.	0.3	52
94	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 485-493.	1.5	52
95	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 720-726.	0.3	51
96	An International Randomized Multicenter Comparison of Nasal Potential Difference Techniques. Chest, 2010, 138, 919-928.	0.4	50
97	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug and Alcohol Dependence, 2020, 217, 108335.	1.6	50
98	Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. Journal of Pediatrics, 2006, 149, 658-662.e1.	0.9	49
99	Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis, 2020, 19, 595-601.	0.3	49
100	Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 293-299.	0.3	48
101	A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatric Pulmonology, 2002, 33, 90-98.	1.0	46
102	Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatric Pulmonology, 2010, 45, 291-300.	1.0	46
103	Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. Pediatric Pulmonology, 2004, 38, 204-209.	1.0	45
104	Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. Pediatric Pulmonology, 2013, 48, 649-657.	1.0	44
105	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	0.9	44
106	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	1.0	43
107	Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatric Pulmonology, 2022, 57, .	1.0	41
108	Tissue-Specific Fc Î³ and Complement Receptor Expression by Alveolar Macrophages Determines Relative Importance of IgG and Complement in Promoting Phagocytosis of Pseudomonas aeruginosa. Pediatric Research, 1994, 35, 68-77.	1.1	40

#	Article	IF	Citations
109	Safety and Preliminary Clinical Activity of a Novel Pancreatic Enzyme Preparation in Pancreatic Insufficient Cystic Fibrosis Patients. Pancreas, 2006, 32, 258-263.	0.5	39
110	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	1.0	39
111	Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. Journal of Cystic Fibrosis, 2010, 9, 332-338.	0.3	39
112	Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Current Medical Research and Opinion, 2013, 29, 947-956.	0.9	38
113	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 763-769.	0.3	38
114	Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thoracic Society, 2021, 18, 1397-1405.	1.5	38
115	Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. , 1998, 25, 83-87.		37
116	Patterns of medical practice in cystic fibrosis: Part I. Evaluation and monitoring of health status of patients. , 1999, 28, 242-247.		37
117	Pitfall in the Use of Genotype Analysis as the Sole Diagnostic Criterion for Cystic Fibrosis. Pediatrics, 1999, 103, 823-826.	1.0	37
118	Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study. Pediatric Pulmonology, 2001, 32, 122-128.	1.0	37
119	Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease. Clinical Reviews in Allergy and Immunology, 2008, 35, 135-153.	2.9	37
120	Coefficients of Fat and Nitrogen Absorption in Healthy Subjects and Individuals with Cystic Fibrosis. Journal of Pediatric Pharmacology and Therapeutics, 2007, 12, 47-52.	0.3	37
121	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	0.9	36
122	Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function. Journal of Pediatrics, 2013, 163, 1152-1157.e2.	0.9	36
123	Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 1398-1406.	1.5	36
124	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. Journal of Cystic Fibrosis, 2019, 18, 94-101.	0.3	36
125	The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis. Paediatric Drugs, 2009, 11, 101-113.	1.3	35
126	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 372-379.	0.3	35

#	Article	IF	Citations
127	Relationship of Antibiotic Treatment to Recovery after Acute FEV₁ Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 937-942.	1.5	35
128	Transfer of the Human Alpha1-Antitrypsin Gene into Pulmonary MacrophagesIn Vivo. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 591-601.	1.4	34
129	Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 783-790.	0.3	34
130	Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 284-291.	0.3	34
131	THERAPIES AIMED AT AIRWAY INFLAMMATION IN CYSTIC FIBROSIS. Clinics in Chest Medicine, 1998, 19, 505-513.	0.8	33
132	Non-viral gene transfer therapy for cystic fibrosis. Expert Opinion on Biological Therapy, 2003, 3, 449-458.	1.4	33
133	A multiâ€center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 252-263.	1.0	32
134	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 2018, 15, 225-233.	1.5	32
135	Anti-Inflammatory Medications for Cystic Fibrosis Lung Disease. Treatments in Respiratory Medicine, 2005, 4, 255-273.	1.4	31
136	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation, 2012, 2, 163-175.	0.0	31
137	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 943-953.	1.0	31
138	Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 777-783.	0.3	31
139	Behavioral and Nutritional Treatment for Preschool-Aged Children With Cystic Fibrosis. JAMA Pediatrics, 2015, 169, e150636.	3.3	31
140	Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. Journal of Cystic Fibrosis, 2011, 10, 453-459.	0.3	30
141	Cross-Sectional and Longitudinal Studies of Naturally Occurring Antibodies to Pseudomonas aeruginosa in Cystic Fibrosis Indicate Absence of Antibody-Mediated Protection and Decline in Opsonic Quality after Infection. Journal of Infectious Diseases, 1995, 172, 453-461.	1.9	28
142	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Journal of Clinical and Translational Science, 2018, 2, 334-342.	0.3	28
143	Estimating effectiveness in an observational study: A case study of dornase alfa in cystic fibrosis. Journal of Pediatrics, 1999, 134, 734-739.	0.9	27
144	The Pathologic Characteristics of Interstitial Pneumonia in Cystic Fibrosis: A Retrospective Autopsy Study. American Journal of Clinical Pathology, 1989, 91, 522-530.	0.4	24

#	Article	IF	Citations
145	A Pipeline of Therapies for Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 611-626.	0.8	24
146	Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012. Journal of Pediatrics, 2014, 165, 1091-1097.e2.	0.9	24
147	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis, 2015, 14, 370-375.	0.3	24
148	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.3	24
149	Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Alimentary Pharmacology and Therapeutics, 2004, 20, 1365-1371.	1.9	23
150	Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661882018.	1.0	23
151	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatric Pulmonology, 2008, 43, 739-744.	1.0	21
152	Early childhood wheezing is associated with lower lung function in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 745-750.	1.0	21
153	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 828-834.	1.0	21
154	BMI fails to identify poor nutritional status in stunted children with CF. Journal of Cystic Fibrosis, 2017, 16, 158-160.	0.3	20
155	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	1.0	19
156	Inflammatory Mediators in CF Patients. , 2002, 70, 409-432.		18
157	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995â€“2005. Journal of Cystic Fibrosis, 2013, 12, 332-337.	0.3	18
158	Oneâ€year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatric Pulmonology, 2016, 51, 372-378.	1.0	18
159	Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study. PLoS ONE, 2013, 8, e73286.	1.1	18
160	Beta 2 adrenergic receptor polymorphisms in cystic fibrosis. Pediatric Pulmonology, 2005, 39, 544-550.	1.0	16
161	Clinical use of tobramycin inhalation solution (TOBIÂ®) shows sustained improvement in FEV₁ in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 529-536.	1.0	16
162	Pulmonary function outcomes for assessing cystic fibrosis care. Journal of Cystic Fibrosis, 2015, 14, 376-383.	0.3	16

#	Article	IF	Citations
163	A Comparative Study of Lysozyme and Its Secretion by Tracheal Epithelium. Experimental Lung Research, 1982, 3, 175-181.	0.5	15
164	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 966-972.	1.0	15
165	Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clinical Investigation, 2013, 3, 723-729.	0.0	15
166	Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. Journal of Cystic Fibrosis, 2017, 16, 283-290.	0.3	15
167	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 496-502.	0.3	15
168	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. Journal of Pediatrics, 2020, 223, 183-185.	0.9	15
169	Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1673-1676.	2.5	14
170	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis, 2018, 17, 503-510.	0.3	14
171	Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing. PLoS ONE, 2022, 17, e0265129.	1.1	13
172	Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis. Pediatric Pulmonology, 2015, 50, 447-455.	1.0	12
173	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology, 2021, 56, 823-836.	1.0	11
174	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of Cystic Fibrosis, 2021, 20, 965-971.	0.3	11
175	Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of Cystic Fibrosis, 2021, 20, 1010-1017.	0.3	11
176	Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterology Research and Practice, 2010, 2010, 1-7.	0.7	10
177	What Is Cystic Fibrosis?. JAMA - Journal of the American Medical Association, 2022, 327, 191.	3.8	10
178	Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis. Clinical Investigation, 2013, 3, 731-741.	0.0	9
179	Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of Cystic Fibrosis, 2021, 20, 39-45.	0.3	9
180	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1026-1034.	0.3	9

#	Article	IF	Citations
181	Murine Models of CF Airway Infection and Inflammation. , 2002, 70, 495-516.		8
182	Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening. Clinica Chimica Acta, 2011, 412, 1376-1381.	0.5	8
183	Inhaled Hypertonic Saline in Infants and Young Children With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2316-7.	3.8	8
184	Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 476-479.	0.9	7
185	Safety, Tolerability, and Plasma Exposure of Tiotropium RespimatÂ® in Children and Adults with Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 137-144.	0.7	7
186	Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 257-263.	0.3	7
187	Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatric Pulmonology, 2021, 56, 2833-2844.	1.0	7
188	Dornase alfa and progression of lung disease in cystic fibrosis. Pediatric Pulmonology, 2008, 43, S24-S28.	1.0	6
189	Pooled analysis of tiotropium RespimatÂ® pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology and Therapeutics, 2014, 29, 217-223.	1.1	6
190	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Pediatric Pulmonology, 2017, 52, 1013-1019.	1.0	6
191	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric Pulmonology, 2018, 53, 43-49.	1.0	6
192	Location and Duration of Treatment of Cystic Fibrosis Respiratory Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 278-278.	2.5	5
193	Rapid intravenous desensitization to colistin. Annals of Allergy, Asthma and Immunology, 2012, 109, 361-362.	0.5	5
194	Clinical care for cystic fibrosis: preparing for the future now. Lancet Respiratory Medicine,the, 2020, 8, 10-12.	5.2	5
195	Acute Loxapine Intoxication in a Child. Journal of Analytical Toxicology, 1982, 6, 258-259.	1.7	4
196	Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes. Journal of Clinical and Translational Science, 2018, 2, 156-162.	0.3	4
197	Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulmonary Therapy, 2021, 7, 281-293.	1.1	3
198	Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis, 2022, 21, 96-103.	0.3	2

#	Article	IF	Citations
199	Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology. , 1997, 24, 137.		2
200	Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution. Human Gene Therapy, 2004, .	1.4	2
201	Efficacy of the Flutter Device for Airway Mucus Clearance in Patients with Cystic Fibrosis. Survey of Anesthesiology, 1995, 39, 133.	0.1	0
202	Reply to: Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. Journal of Pediatrics, 1996, 128, 165-166.	0.9	0
203	Reply. Journal of Pediatrics, 2016, 172, 228-229.	0.9	0
204	Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 405-406.	2.5	0